– USA, MA – NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Brad Fluegel to its Board of Directors, effective as of July 1, 2022.
“We are pleased to welcome Brad to the NeuroMetrix Board of Directors,” said Chairman and CEO, Dr. Shai N. Gozani. “His extensive strategic and operational experience in value-based care, medical technology, digital health and overall thought leadership in healthcare aligns well with the key elements of our growth strategy. “We look forward to working closely with Brad and leveraging his leadership and insights for the benefit of the Company.”
About Bradley M. Fluegel
Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology. He has held numerous leadership roles over the past 25+ years, primarily in healthcare strategy and business development. Most recently, Mr. Fluegel was SVP, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role, he was responsible for leading all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development, and market planning. Before this role, he served as Walgreens’ CSBO. Mr. Fluegel is a senior advisor to Walgreens.
Previously, Mr. Fluegel was executive in residence at Health Evolution Partners. Earlier in his career, he was EVP, Chief Strategy and External Affairs Officer at Wellpoint (now Elevance Health), SVP of National Accounts and VP, Enterprise Strategy at Aetna, CEO for Reden & Anders (Optum Consulting), and principal at Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice serving the health care industry.
Mr. Fluegel currently serves on the Boards of Directors of Performant Financial Corporation, Premera Blue Cross, AdhereHealth, and the Metropolitan Jewish Health System in New York City. Mr. Fluegel was also on the Boards of Fitbit and Itamar Medical, both Nasdaq traded companies until they were recently acquired.
“NeuroMetrix presents the exciting challenge of a commercial-stage company with unique products that address large and important unmet needs in the areas of neurology and chronic pain,” said Mr. Fluegel. “I look forward to working with the NeuroMetrix team as the company grows and continues to positively impact the lives of individual patients and more broadly, population health.”
Mr. Fluegel earned a master’s degree in public policy from Harvard University and a bachelor’s degree in business administration from the University of Washington. He is a lecturer in the Health Care Management Department at the Wharton School of the University of Pennsylvania.
About NeuroMetrix
NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through innovative medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell is a wearable neuromodulation technology indicated for the treatment of fibromyalgia symptoms and chronic lower extremity pain.
For more information: https://www.neurometrix.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.